TABLE 1.

The efficacy of commercial PRRSV MLVs to NADC30-like isolates.

MLVs	Company	Inoculated isolate	Protection efficacy	References
VR-2332	Boehringer-Ingelheim, Germany	HNjz15	Ineffective	Bai et al., 2016
JXA1-P80	Pulike Biological Engineering Co. Ltd	HNjz15	Ineffective	Bai et al., 2016
HuN4-F112	Harbin Weike Biotechnology Development Company	HNjz15	Ineffective	Bai et al., 2016
GDr180	Guangdong Yongshun Biological Pharmaceutical Co. Ltd	HNjz15	Ineffective	Bai et al., 2016
TJM-F92	Qingdao Yibang Biological Engineering Co. Ltd	HNjz15	Ineffective	Bai et al., 2016
Ingelvac PRRS MLV	No detail	CHsx1401	Some beneficial efficiency in shortening the period of clinical fever and in improving the growth performance	Zhou et al., 2017
JXA1-R	No detail	CHsx1401	Extremely limited cross-protection efficacy	Zhou et al., 2017
PRRSV HB-1/3.9-P40	Non-commercial	CHsx1401	Extremely limited cross-protection efficacy	Zhou et al., 2017
TJM-F92	Sinovet (Beijing) Biotechnology Co. Ltd	HN201605	Cross-protection	Zhang et al., 2018
VR-2332	Boehringer-Ingelheim	v2016/ZJ/09-03	Cross-protection in improving growth performance, decreasing the percentage of viremic pigs, and reducing gross lung lesions	Chai et al., 2020
TJM-F92	Zoetis	v2016/ZJ/09-03	Limited protection in improving growth performance, decreasing the percentage of viremic pigs, and reducing gross lung lesions	Chai et al., 2020